OR WAIT null SECS
February 16, 2024
The need for preclinical testing expertise is growing as molecular complexity increases.
October 05, 2023
POINT is a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.
September 25, 2023
The company is currently developing EVX-101 as an adjunctive treatment for MDD due to patients experiencing an inadequate response to first-line antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors SNRIs.
September 02, 2023
There are many promising trials in the pipeline that may bring big news for major therapeutic areas.
August 21, 2023
The expanded operations will also support the start of proline/alanine/serine (PAS)-nomacopan clinical trials in geographic atrophy (GA).
August 10, 2023
The initial collaboration between the two companies began in 2017 with an extension announced in 2021.
July 27, 2023
The partnership is an extension of the collaboration from AbbVie and Scripps Research that was formed in 2019, according to the press release.
June 08, 2023
The document builds on key concepts outlined in ICH E8(R1) General Considerations for Clinical Studies.
April 28, 2023
clonoSEQ Assay is authorized by FDA for MRD assessment in lymphoid malignancies and is highly accurate, sensitive, and standardized compared to other technologies used for disease burden assessment.
January 20, 2023
The efficacy data across multiple clinical endpoints and a favorable safety profile support the potential of AMB-05X as a best-in-class therapy for the treatment of TGCT regardless of surgical resectability.